NOVASIGHT IS A GROWING MEDICAL DEVICE COMPANY WITH ITS FLAGSHIP PRODUCT – CURESIGHT™ – FDA CLEARED AND CE MARKED REMOTE DIGITAL EYE TRACKING BASED AMBLYOPIA TREATMENT SYSTEM, THE ONLY DIGITAL DICHOPTIC THERAPY FOR AMBLYOPIA PROVEN TO BE NON-INFERIOR TO THE PATCH.

ECS01

NOVASIGHT IS A GROWING MEDICAL DEVICE COMPANY WITH ITS FLAGSHIP PRODUCT – CURESIGHT™ – FDA CLEARED AND CE MARKED REMOTE DIGITAL EYE TRACKING BASED AMBLYOPIA TREATMENT SYSTEM, THE ONLY DIGITAL DICHOPTIC THERAPY FOR AMBLYOPIA PROVEN TO BE NON-INFERIOR TO THE PATCH.

R.Yam^1,*

¹NovaSight, Airport City, Israel

Established in 2016, NovaSight is a growing ophthalmology medical device company with a vision to change the lives of millions by introducing eye-tracking-based vision care solutions and data analytics into fun and engaging medical devices with an emphasis on the unique needs and attention spans of children. NovaSight is focused on three main segments: Amblyopia treatment, Myopia prevention and Vision diagnostics.

Commercially available in the US and Italy since early 2023, CureSight™ is an FDA-cleared and CE-marked amblyopia treatment system, designed to replace the traditional eye patching. The treatment is carried out while the patient watches their favorite streamed content from the comfort of their home. To date, CureSight is the only solution that has proven effective in a pivotal study against the gold standard patching in children.

By tracking the gaze position of the dominant eye in real-time, the CureSight system blurs its center of vision, while keeping the rest of the image sharp, providing the amblyopic eye with a normal, high-contrast, image. This stimulates the brain to complete the blurred image from the amblyopic eye, improving its acuity and developing stereoacuity as the eyes learn to work together. In addition, the CureSight system is connected to a dedicated cloud platform which allows the physician to monitor treatment progress and compliance remotely.

Since launch earlier last year, CureSight had gained strong adoption by both eye care providers and patients, with over 250 eye care providers already enrolled in the CureSight Referral Program. NovaSight is continuously onboarding additional prominent clinics, resulting in the active availability of the CureSight Referral Program in 35 states with over 650 patients referred so far.

The company’s goals include a global launch of CureSight, Europe launch of the EyeSwift PRO, and further development of additional products.